A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors

Mari C. Vázquez‐Borrego(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Raúl M. Luque(Instituto de Salud Carlos III), Rosa Ortega‐Salas(Instituto Maimónides de Investigación Biomédica de Córdoba), Manuel D. Gahete(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Álvaro Toledano-Delgado(Instituto Maimónides de Investigación Biomédica de Córdoba), Miguel Á. Japón(Instituto de Biomedicina de Sevilla), Alexandre Vasiljevic(Centre de Recherche en Neurosciences de Lyon), Eva Venegas‐Moreno(Hospital Universitario Virgen del Rocío), Michael D. Culler(Ipsen (United States)), Heather Halem(Ipsen (United States)), Gérald Raverot(Université Claude Bernard Lyon 1), Alejandro Ibáñez‐Costa(Instituto de Salud Carlos III), Cristóbal Blanco-Acevedo(Instituto Maimónides de Investigación Biomédica de Córdoba), Justo P. Castaño(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), David A. Cano(State University of New York), Jason E. Hill(Essen BioScience (United States)), Alfonso Soto‐Moreno(Instituto de Biomedicina de Sevilla), Shengwen Zhang(Indiana University School of Medicine), Vandana Gupta(Essen BioScience (United States)), Ana Barrera-Martín(Instituto Maimónides de Investigación Biomédica de Córdoba), María A. Gálvez(Hospital Universitario Reina Sofía), Marcelo Páez-Pereda(Essen BioScience (United States))
Clinical Cancer Research
October 17, 2019
Cited by 52


Related Papers